Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas
- 3 March 2022
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 162, e99-e119
Abstract
No abstract availableKeywords
Funding Information
- Meningioma Mommas
This publication has 16 references indexed in Scilit:
- Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapyClinical Epigenetics, 2013
- Functions of DNA methylation: islands, start sites, gene bodies and beyondNature Reviews Genetics, 2012
- Impaired survival and long-term neurological problems in benign meningiomaNeuro-Oncology, 2012
- Decellularized Porcine Brain Matrix for Cell Culture and Tissue Engineering ScaffoldsTissue Engineering Part A, 2011
- Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationMolecular Cancer, 2010
- LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATIONNeurosurgery, 2009
- Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients. A Multicenter, Retrospective Study of the Rare Cancer NetworkInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteriaNeurosurgical Focus, 2008
- Evolution of decitabine developmentCancer, 2008
- Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysisSurgical Neurology, 1986